Drug Trial Radar · NCT05270525
Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
70
Actual
Start
May 27, 2022
Primary completion
Mar 1, 2027
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAIndustry
- Sponsor type
- Industry
- Collaborators
- University of Alabama at Birmingham
- First posted
- Mar 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat chronic obstructive pulmonary disease (COPD). COPD is a long-lasting swelling of the airways that makes it hard to breathe. Researchers want to learn if a trial medicine called ensifentrine can help treat sputum caused by COPD. In this trial, researchers will compare a trial medicine called ensifentrine to a placebo. A placebo looks like the trial medicine but has no medicine in it. Using a placebo helps researchers better understand the effects of a trial medicine. The goal of this trial is to learn about the effect of ensifentrine on a substance found in mucus (sputum) from the lungs that may be a sign of inflammation in participants with COPD.
Conditions
- Pulmonary Disease, Chronic Obstructive, COPD
Interventions
EnsifentrineDrug
Ensifentrine administered twice daily by oral inhalation via a standard jet nebulizer.
PlaceboDrug
Placebo matching ensifentrine administered twice daily by oral inhalation via a standard jet nebulizer.
LABA/LAMADrug
Background treatment of LAMA/LABA administered per product approved label delivered by oral inhalation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Absolute Change From Baseline in Sputum Neutrophil Cell NumbersTime frame: Baseline and 8 Weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Michigan
Ann Arbor, Michigan
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.